{
    "data": [
        {
            "id": "4402626",
            "title": "Tonix Pharmaceuticals promotes Fogarty to CTO",
            "description": "<html><body><ul> <li>Tonix Pharmaceuticals Holding (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/TNXP\" title=\"Tonix Pharmaceuticals Holding Corp.\">TNXP</a></span>) has announced the promotion of Siobhan Fogarty to <a href=\"https://seekingalpha.com/pr/19990139-tonix-pharmaceuticals-promotes-siobhan-fogarty-to-chief-technical-officer\">Chief Technical Officer</a>, effective immediately.</li> <li>Ms. Fogarty joined Tonix in 2016 and previously served as Executive Vice President of Product Development.</li> <li>In December, Tonix announced that the U.S. FDA assigned<span class=\"paywall-full-content invisible\"> a Prescription Drug User Fee Act goal date of August 15, 2025, for a decision on marketing authorization for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia. </span> </li> <li class=\"paywall-full-content invisible\">TNX-102 SL is a non-opioid, centrally-acting analgesic. Fibromyalgia is a common chronic pain condition that affects mostly women.</li> <li class=\"paywall-full-content invisible\">TNXP <span class=\"red\">-17.9%</span> premarket to $0.16.</li> </ul> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402626-tonix-pharmaceuticals-promotes-fogarty-to-cto",
            "pub_date": "2025-02-04 15:46:57",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402628",
            "title": "Pfizer in charts: Primary Care revenue +26.5% Y/Y, Specialty Care +12.3%, and Oncology +27.4% in Q4",
            "description": "<html><body><div>\n<a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE1.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE1_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE2.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE2_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE3.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE3_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE4.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_PFE4_thumb1.png\" width=\"100%\"/></a>\n</div>\n</body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402628-pfizer-in-charts-primary-care-revenue-265-yy-specialty-care-123-and-oncology-274-in-q4",
            "pub_date": "2025-02-04 15:48:51",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402609",
            "title": "Vacasa gains as Davidson Kempner offers $5.25 a share in takeover offer",
            "description": "<html><body><p>Vacasa (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/VCSA\" title=\"Vacasa, Inc.\">VCSA</a></span>)<span style=\"color: #008000;\"> rose 2.4%</span> in premarket trading after holder Davidson Kempner Capital offered $5.25 a share in a takeover bid, more than its $5.02 sale to Casago.</p> <p>Davidson Kempner submitted a non-binding bid for $5.25 in a letter on Wednesday, according to<span class=\"paywall-full-content invisible\"> a</span><a class=\"paywall-full-content invisible\" href=\"https://seekingalpha.com/filing/9502866\" rel=\"noopener\" target=\"_blank\" title=\" 13D/A filing.\"> 13D/A filing. </a><span class=\"paywall-full-content invisible\">The proposed transaction is not subject to any financing condition.</span></p> <p class=\"paywall-full-content invisible\">The bid comes after Vacasa<a href=\"https://seekingalpha.com/news/4391452-vacasas-outstanding-shares-to-be-acquired-for-502-per-share-in-cash\" rel=\"noopener\" target=\"_blank\" title=\" agreed to a sale to Casago \"> agreed to a sale to Casago </a> in late December.</p> <p class=\"paywall-full-content invisible\">\"Unfortunately, this strategic review resulted in the acceptance by the Special Committee and the Board of an inadequate and conditional offer by Casago Holdings, LLC (“<u>Casago</u>”) that undervalues Vacasa, does not treat all stockholders alike, and is not in the best interest of all Vacasa stakeholders,\" Davidson Kempner said in the filing.</p> </body></html>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396680617/image_1396680617.jpg",
            "link": "https://seekingalpha.com/news/4402609-vacasa-gains-as-davidson-kempner-offers-5_25-a-share-in-takeover-offer",
            "pub_date": "2025-02-04 15:41:33",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402528",
            "title": "Stock index futures mixed as China hits back with tariffs on U.S. imports",
            "description": "<html><body><p class=\"MsoNormal\">Stock index futures were looking for direction on Tuesday as China retaliated with a levy of tariffs on imports of multiple U.S. products.</p> <p class=\"MsoNormal\">S&amp;P 500 futures (<span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/SPX\" title=\"S&amp;P 500 Index\">SPX</a></span></span></span></span></span></span>) <span style=\"color: #008000;\">+0.1%</span>, Nasdaq 100 futures (<a href=\"https://seekingalpha.com/symbol/US100:IND\" title=\"NASDAQ 100 Futures\">US100:IND</a>) <span style=\"color: #008000;\">+0.3%</span>, and Dow futures (<a href=\"https://seekingalpha.com/symbol/INDU\" title=\"Dow Jones Futures\">INDU</a>) <span style=\"color: #ff0000;\">-0.1%</span>.</p> <p class=\"MsoNormal\">The 10-year<span class=\"paywall-full-content invisible\"> Treasury yield (</span><a class=\"paywall-full-content invisible\" href=\"https://seekingalpha.com/symbol/US10Y\" title=\"United States 10-Year Bond Yield\">US10Y</a><span class=\"paywall-full-content invisible\">) rose 1 basis point to 4.58%. The 2-year yield (</span><a class=\"paywall-full-content invisible\" href=\"https://seekingalpha.com/symbol/US2Y\" title=\"United States 2-Year Bond Yield\">US2Y</a><span class=\"paywall-full-content invisible\">) was flat at 4.27%.</span></p> <p class=\"MsoNormal paywall-full-content invisible\">The <a href=\"https://seekingalpha.com/news/4402411-tit-for-tat-china-hits-back-with-tariffs-on-u_s_-coal-lng-vehicles\" rel=\"noopener\" target=\"_blank\" title=\"Chinese government\">Chinese government</a> said it would implement a 15% tariff on coal and liquefied natural gas products, as well as a 10% tariff on crude oil, agricultural machinery, and large-displacement cars.</p> <p class=\"MsoNormal paywall-full-content invisible\">Wall Street closed lower on Monday after President Donald Trump announced new tariffs on Canada and Mexico over the weekend. While it was a red day, markets were able to recoup some earlier losses after delays were announced against tariffs towards Mexico.</p> <p class=\"MsoNormal paywall-full-content invisible\">\"The past 24 hours have seen a big roundtrip for many assets classes as strongly negative sentiment gave way to a relief rally on news that the planned 25% tariffs against Mexico and Canada would be delayed,\" Deutsche Bank's Jim Reid said.</p> <p class=\"MsoNormal paywall-full-content invisible\">Although U.S. futures have dipped, along with the rest of Asia after China's immediate retaliation came though, markets remain higher and are rebounding from yesterday's selloff, Reid added.</p> <p class=\"MsoNormal paywall-full-content invisible\">\"Taxing goods from China is still happening, and China has retaliated. The inflation consequences of these taxes are less obvious to US consumers,\" UBS' Paul Donovan said.</p> <p class=\"MsoNormal paywall-full-content invisible\">On the earnings side, Google parent <a href=\"https://seekingalpha.com/news/4402150-alphabet-q4-preview-eyes-on-ad-business-cloud-sales-and-capital-spend\" rel=\"noopener\" target=\"_blank\" title=\"Alphabet\">Alphabet</a> (<a href=\"https://seekingalpha.com/symbol/GOOGL\" title=\"Alphabet Inc.\">GOOGL</a>) (<a href=\"https://seekingalpha.com/symbol/GOOG\" title=\"Alphabet Inc.\">GOOG</a>) is expected to release its fourth quarter results. </p> <p class=\"MsoNormal paywall-full-content invisible\">Traders were also awaiting the December Job Openings and Labor Turnover Survey report, which will land during market hours, and is expected to fall to 8.010M.</p> <p class=\"MsoNormal paywall-full-content invisible\">U.S. job vacancy data is due. The survey response rate is tiny, making the data an imprecise guide, Donovan said.</p> </body></html>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/165581156/image_165581156.jpg",
            "link": "https://seekingalpha.com/news/4402528-sp500-nasdaq-dow-jones-outlook-stock-market",
            "pub_date": "2025-02-04 15:42:07",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402616",
            "title": "Microbix receives C$2.4M from exercise of warrants",
            "description": "<html><body><ul> <li dir=\"ltr\">Microbix Biosystems (<span class=\"ticker-hover-wrapper\">TSX:<a href=\"https://seekingalpha.com/symbol/MBX:CA\" title=\"Microbix Biosystems Inc.\">MBX:CA</a></span>) <a href=\"https://seekingalpha.com/pr/19990122-microbix-receives-2_4-million-from-exercise-of-warrants\" rel=\"noopener\" target=\"_blank\" title=\"said\">said</a> on Tuesday that it has received C$ 2.4M in new equity capital from the partial exercise of expiring share purchase warrants.</li> <li dir=\"ltr\">The warrants were issued in connection with a private placement undertaken in January, 2020, and had an<span class=\"paywall-full-content invisible\"> exercise price of C$ 0.36 and a five-year term. </span> </li> <li class=\"paywall-full-content invisible\" dir=\"ltr\">Microbix intends to use this additional capital to broaden its product development capabilities, to expand its manufacturing capacity, and to make more improvements to the efficiency of its operations. </li> <li class=\"paywall-full-content invisible\" dir=\"ltr\">A portion of the proceeds may also be used to reduce debt or, to fund additional share repurchases under Microbix’s previously-disclosed Normal-Course Issuer Bid (“NCIB”).</li> <li class=\"paywall-full-content invisible\" dir=\"ltr\">After addition of all new shares resulting from 2020 Warrant exercises, Microbix has 142.3M common shares outstanding. </li> <li class=\"paywall-full-content invisible\" dir=\"ltr\">There are no further Microbix warrants outstanding following the expiry of this series. Microbix’s cash and equivalents balance stands at over C$ 15M after the exercise of these last 2020 Warrants.</li> </ul> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402616-microbix-receives-c2_4m-from-exercise-of-warrants",
            "pub_date": "2025-02-04 15:39:33",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402624",
            "title": "Lancaster Colony GAAP EPS of $1.78 misses by $0.16, revenue of $509.3M beats by $13.87M",
            "description": "<html><body><ul>\n<li>Lancaster Colony <a href=\"https://seekingalpha.com/pr/19990248-lancaster-colony-reports-second-quarter-sales-and-earnings\">press release</a>  (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/LANC\" title=\"Lancaster Colony Corporation\">LANC</a></span>): Q2  GAAP EPS of $1.78 <font color=\"red\"> misses by $0.16</font>.</li>\n<li>Revenue of $509.3M (+4.8% Y/Y) <font color=\"green\"> beats by $13.87M</font>.</li>\n<li>Retail segment sales volume, measured in pounds shipped, increased 6.0%. Excluding the perimeter-of-the-store bakery product lines that we exited in March 2024, Retail net sales increased 8.4% and Retail sales volume increased 7.4%.</li>\n</ul>\n</body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402624-lancaster-colony-gaap-eps-of-178-misses-by-016-revenue-of-5093m-beats-by-1387m",
            "pub_date": "2025-02-04 15:40:39",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402614",
            "title": "Cummins reports mixed Q4 results; initiates FY25 outlook",
            "description": "<html><body><ul>\n<li>Cummins <a href=\"https://seekingalpha.com/pr/19990253-cummins-reports-strong-fourth-quarter-and-full-year-2024-results-incurs-charges-associated\">press release</a>  (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/CMI\" title=\"Cummins Inc.\">CMI</a></span>): Q4  GAAP EPS of $3.02 <font color=\"red\"> misses by $1.62</font>.</li>\n<li>Revenue of $8.4B (-1.6% Y/Y) <font color=\"green\"> beats by $310M</font>.</li>\n<li>EBITDA in the fourth quarter was 12.1% of sales.</li>\n<li>\n<strong>Full year 2025 revenues</strong> expected to range from down 2% to up 3% <strong>vs 2.78% Y/Y estimated growth</strong>; EBITDA expected to range between 16.2% and 17.2% of sales</li>\n</ul>\n</body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402614-cummins-reports-mixed-q4-results-initiates-fy25-outlook",
            "pub_date": "2025-02-04 15:32:46",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402615",
            "title": "Madison Square Garden GAAP EPS of $0.05 misses by $0.25, revenue of $357.8M beats by $5.17M",
            "description": "<html><body><ul> <li>Madison Square Garden <a href=\"https://seekingalpha.com/pr/19990261-madison-square-garden-sports-corp-reports-fiscal-2025-second-quarter-results\">press release</a> (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/MSGS\" title=\"Madison Square Garden Sports Corp.\">MSGS</a></span>): Q2 GAAP EPS of $0.05 <span style=\"color: red;\"> misses by $0.25</span>.</li> <li>Revenue of $357.8M (+9% Y/Y) <span style=\"color: green;\"> beats by $5.17M</span>.</li> <li>This increase was primarily due to higher ticket-related revenues, suite revenues, sponsorship and signage revenues, revenues from league distributions, food, beverage and merchandise<span class=\"paywall-full-content invisible\"> sales and local media rights fees. The Knicks and Rangers played a combined three more regular season games at The Garden during the fiscal 2025 second quarter as compared to the prior year period.</span> </li> </ul> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402615-madison-square-garden-gaap-eps-of-0_05-misses-by-0_25-revenue-of-357_8m-beats-by-5_17m",
            "pub_date": "2025-02-04 15:33:28",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402608",
            "title": "TransDigm Group Non-GAAP EPS of $7.83 beats by $0.09, revenue of $2B misses by $30M",
            "description": "<html><body><ul> <li>TransDigm Group <a href=\"https://seekingalpha.com/pr/19990222-transdigm-group-reports-fiscal-2025-first-quarter-results\">press release</a> (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/TDG\" title=\"TransDigm Group Incorporated\">TDG</a></span>): Q1 Non-GAAP EPS of $7.83 <span style=\"color: green;\"> beats by $0.09</span>.</li> <li>Revenue of $2B (+11.7% Y/Y) <span style=\"color: red;\"> misses by $30M</span>.</li> <li> <p>TransDigm expects fiscal 2025 financial guidance to be as follows:</p> <ul> <li>Net sales are anticipated to be in the range<span class=\"paywall-full-content invisible\"> of $8,750 million to $8,950 million vs $8.90B consensus compared with $7,940 million in fiscal 2024, an increase of 11.5% at the midpoint;</span> </li> <li class=\"paywall-full-content invisible\">Net income is anticipated to be in the range of $1,925 million to $2,037 million compared with $1,715 million in fiscal 2024, an increase of 15.5% at the midpoint;</li> <li class=\"paywall-full-content invisible\">Earnings per share is expected to be in the range of $32.27 to $34.19 per share based upon weighted average shares outstanding of 58.15 million shares, compared with $25.62 per share in fiscal 2024, which is an increase of 29.7% at the midpoint;</li> <li class=\"paywall-full-content invisible\">EBITDA As Defined is anticipated to be in the range of $4,615 million to $4,755 million compared with $4,173 million in fiscal 2024, an increase of 12.3% at the midpoint (corresponding to an EBITDA As Defined margin guide of approximately 52.9% for fiscal 2025);</li> <li class=\"paywall-full-content invisible\">Adjusted earnings per share is expected to be in the range of $35.51 to $37.43 per share vs $37.44 consensus compared with $33.99 per share in fiscal 2024, an increase of 7.3% at the midpoint; and</li> </ul> </li> </ul> </body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402608-transdigm-group-non-gaap-eps-of-7_83-beats-by-0_09-revenue-of-2b-misses-by-30m",
            "pub_date": "2025-02-04 15:28:25",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4402610",
            "title": "Merck in Charts: KEYTRUDA continues growth trajectory with 18.6% rise in Q4",
            "description": "<html><body><div>\n<a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK1.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK1_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK2.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK2_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK3.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK3_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK4.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK4_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK5.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK5_thumb1.png\" width=\"100%\"/></a><a href=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK6.png\" rel=\"lightbox\" target=\"_blank\"><img src=\"https://static.seekingalpha.com/uploads/2025/2/4/saupload_MRK6_thumb1.png\" width=\"100%\"/></a>\n</div>\n</body></html>",
            "image": null,
            "link": "https://seekingalpha.com/news/4402610-merck-in-charts-keytruda-continues-growth-trajectory-with-186-rise-in-q4",
            "pub_date": "2025-02-04 15:29:28",
            "source": "seekalpha",
            "kind": 1,
            "language": "en"
        }
    ]
}